Ozempic side effects: what the data actually shows
By Iacob Pastina · Independent Researcher · Updated May 2026
Important: Ozempic is FDA-approved for type 2 diabetes
Ozempic (semaglutide) is approved by the FDA to treat type 2 diabetes and reduce cardiovascular risk in adults with T2DM. It is not FDA-approved for weight loss. The same active molecule (semaglutide) is also marketed at a higher dose under the brand name Wegovy, which IS FDA-approved for chronic weight management.
The side-effect rates on this page are for the FDA-approved Ozempic diabetes doses (0.25mg starter / 0.5mg / 1mg / 2mg). Rates at the higher 2.4mg weight-loss dose are higher — see the Wegovy side effects deep dive if you're prescribed semaglutide for weight loss.
The most common Ozempic side effects at diabetes doses are gastrointestinal: nausea (15.8% at 0.5mg / 20.3% at 1mg), diarrhea (8.5-8.8%), vomiting (5-9.2%), and abdominal pain (5.7-6.9%). 98% of GI side effects in the SUSTAIN trials were mild to moderate, peaked during dose escalation, and improved over time. All percentages below come from the FDA-approved Ozempic prescribing information, based on the SUSTAIN program of clinical trials.
Call your doctor or 911 immediately if you experience:
- • Severe upper abdominal pain radiating to the back (possible pancreatitis — call 911)
- • Severe hypoglycemia: confusion, loss of consciousness, seizure (call 911 if unconscious)
- • Difficulty breathing, throat swelling, or widespread hives (call 911)
- • Sudden vision changes — blurred or distorted vision, especially with pre-existing retinopathy (provider call same day)
- • Inability to keep fluids down for 24+ hours (kidney-injury risk — call your provider or ER)
- • Sharp upper-right pain after fatty meals with fever or jaundice (gallbladder — provider call)
- • New or worsening suicidal thoughts (call your provider AND 988)
Report any serious adverse event to FDA MedWatch.
Common side effects: rates from the Ozempic label
Source: FDA-approved prescribing information for Ozempic (semaglutide 0.5mg / 1mg / 2mg), based on the SUSTAIN program of clinical trials in adults with type 2 diabetes. Two columns shown because side-effect rates differ measurably between the 0.5mg and 1mg doses.
| Side effect | Rate at 0.5mg | Rate at 1mg | Severity | When it peaks |
|---|---|---|---|---|
| Nausea | 15.8% | 20.3% | Mild to moderate | Weeks 4-12 (during dose escalation) |
| Diarrhea | 8.5% | 8.8% | Mild to moderate | Weeks 1-4 |
| Vomiting | 5.0% | 9.2% | Mild to moderate | Weeks 4-8 |
| Abdominal pain | 6.9% | 5.7% | Mild cramping (severe pain is a red flag) | Weeks 1-8 |
| Constipation | 5.0% | 3.1% | Mild | Weeks 4-12 |
| Dyspepsia (indigestion) | 2.7% | 3.5% | Mild | Throughout treatment |
| Decreased appetite | — | — | Often perceived as benefit by patients | Weeks 2-12 |
| Hypoglycemia (with sulfonylurea or insulin) | 11.3% | — | Moderate — can be severe if combined with insulin | Throughout treatment |
| Injection site reactions | 0.2% | 0.2% | Mild | First 24 hours after injection |
| Hair loss (telogen effluvium) | Rare at diabetes doses | Rare at diabetes doses | Cosmetic — temporary; more common at weight-loss doses (Wegovy 3%) | Months 3-6 (related to rapid weight loss when it occurs) |
What to expect, week by week
Ozempic uses a 4-week-step titration: 0.25mg starter → 0.5mg → 1mg → optional 2mg, advancing every 4 weeks. The starter dose is not therapeutic for blood glucose; its purpose is GI tolerance.
Weeks 1-4 (0.25mg starter — sub-therapeutic)
What's typical: Mild nausea (5-10% of patients), occasional headache. The starter dose is intentionally not therapeutic for blood glucose; it lets the gut adjust before you reach 0.5mg.
Red flags: Persistent vomiting, severe abdominal pain, allergic reaction symptoms.
Weeks 5-8 (0.5mg — therapeutic minimum)
What's typical: First therapeutic dose for diabetes. Nausea peaks for many users (15.8% baseline). Blood glucose begins to drop measurably; HbA1c improvements show on labs around week 8-12.
Red flags: Hypoglycemia symptoms (especially if on insulin or sulfonylureas — many providers reduce these at this stage). Inability to keep fluids down for 24+ hours.
Weeks 9-12 (continued 0.5mg or escalate to 1mg)
What's typical: GI symptoms typically diminishing on stable dose. If glycemic control is sufficient at 0.5mg, many patients stay there indefinitely. If escalating to 1mg, expect a temporary nausea rebound for 2-4 weeks.
Red flags: New or worsening vision (diabetic retinopathy risk during rapid glucose normalization), severe upper-right abdominal pain (gallbladder).
Weeks 13-16 (1mg)
What's typical: Maintenance dose for many patients. Nausea baseline 20.3%. Most users tolerate steady-state better than escalation periods.
Red flags: Worsening symptoms instead of improving — discuss dose-hold with your provider before considering 2mg.
Weeks 17+ (1mg or 2mg maintenance)
What's typical: Stable dose. Most GI side effects minimal. Continued HbA1c monitoring quarterly. The 2mg dose is approved but used selectively when 1mg provides insufficient glycemic control.
Red flags: Any new symptom that emerges months into treatment warrants a provider call. Vision changes, especially in patients with pre-existing retinopathy, need prompt eye exam.
Management protocols for the most common side effects
Nausea (15.8% at 0.5mg, 20.3% at 1mg)
- • Eat smaller, more frequent meals (5-6 small instead of 3 large)
- • Avoid fatty, fried, spicy, or highly aromatic foods during dose escalation
- • Stay hydrated with small sips throughout the day; ginger or peppermint tea helps many users
- • Take Ozempic on the same day each week — many patients prefer Friday or Saturday so peak effects fall on a low-stress weekend
- • Most providers will hold dose escalation for 4 additional weeks if nausea is intolerable rather than push to 1mg or 2mg
Hypoglycemia management — Ozempic-specific concern
- • Ozempic alone rarely causes hypoglycemia, but combined with insulin or sulfonylureas the risk rises sharply
- • Many endocrinologists reduce sulfonylurea doses by 50% when starting Ozempic, then taper based on glucose readings
- • Insulin doses typically drop 10-20% in the first 4-8 weeks of Ozempic — don't self-adjust without provider guidance
- • Keep glucose tablets or fast-acting carbs (juice, regular soda) accessible; treat any reading under 70 mg/dL
- • Severe hypoglycemia (loss of consciousness, seizure) is a 911 emergency
Diabetic retinopathy — get a baseline eye exam
- • 3% of SUSTAIN-6 patients had retinopathy complications vs 1.8% on placebo — an Ozempic-specific signal
- • The mechanism: rapid blood glucose normalization can transiently worsen pre-existing retinopathy
- • If you have any history of diabetic eye disease, schedule a dilated eye exam BEFORE starting Ozempic
- • Re-examine at every dose change in the first year
- • Sudden vision changes (blurring, distortion, floaters) need same-day provider contact and ophthalmology referral
Diarrhea (8.5-8.8%) and Vomiting (5-9.2%)
- • Maintain hydration as the priority — water plus electrolytes (sports drinks, oral rehydration salts)
- • BRAT diet (bananas, rice, applesauce, toast) for diarrhea
- • Avoid caffeine, alcohol, and dairy during acute symptoms
- • If you cannot keep fluids down for 24 hours, call your provider — risk of dehydration-induced kidney injury, especially for patients with pre-existing kidney disease
Serious side effects — recognize these red flags
Rare but serious. Note: Ozempic carries an additional retinopathy warning that Wegovy does not emphasize the same way — because Ozempic's primary indication (T2DM) means more patients have pre-existing diabetic eye disease.
Pancreatitis
<0.5% (rare but serious)Red-flag symptoms: Severe upper abdominal pain radiating to the back, with persistent nausea or vomiting
Action: STOP Ozempic and seek emergency care immediately. Do not restart without provider clearance.
Diabetic retinopathy complications
3% (vs 1.8% on placebo) — Ozempic-specificRed-flag symptoms: New or worsening blurred vision, especially in patients with pre-existing diabetic retinopathy. Rapid improvement in blood glucose can transiently worsen retinopathy in vulnerable patients.
Action: Schedule a dilated eye exam before starting Ozempic if you have any history of retinopathy, and at every dose change.
Gallbladder problems
1.5% (gallstones)Red-flag symptoms: Sharp upper-right abdominal pain after fatty meals, fever, jaundice. Rapid weight changes — even modest ones at diabetes doses — can precipitate gallstones.
Action: Contact your provider for imaging. May require surgical removal in 0.3-0.6% of cases.
Acute kidney injury
RareRed-flag symptoms: Decreased urine output, swelling, fatigue — usually after persistent vomiting or diarrhea causing dehydration
Action: Maintain aggressive hydration during GI symptoms. If you cannot keep fluids down for 24 hours, contact your provider or ER.
Severe hypoglycemia
Variable — primarily in patients on insulin or sulfonylureasRed-flag symptoms: Confusion, loss of consciousness, seizure, severe shakiness with sweating
Action: If conscious and able to swallow, treat with 15g fast-acting carbs (juice, glucose tablets). If unconscious or unable to swallow, this is a 911 emergency. Discuss insulin/sulfonylurea dose reduction with your prescriber when starting Ozempic.
Severe allergic reaction (anaphylaxis)
Rare (<0.1%)Red-flag symptoms: Difficulty breathing, throat or facial swelling, widespread hives, drop in blood pressure
Action: CALL 911. Do not drive yourself.
Suicidal ideation
Under FDA post-marketing review — no causal link establishedRed-flag symptoms: New or worsening depression, mood changes, self-harm thoughts
Action: Contact your provider AND report to FDA MedWatch (1-800-FDA-1088). The 988 Suicide & Crisis Lifeline is available 24/7.
The boxed warning: thyroid C-cell tumors
Ozempic carries a boxed warning— the FDA's strongest warning level — for thyroid C-cell tumors. This is based on rodent studies; no causal link has been established in humans.
Ozempic is contraindicated in patients with:
- • Personal or family history of medullary thyroid carcinoma (MTC)
- • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Your prescriber should screen for these before initiating Ozempic. If a telehealth provider does not ask about thyroid history during intake, treat that as a quality flag — programs with stronger clinical oversight (board-certified endocrinology or obesity medicine physicians, comprehensive intake) catch this systematically.
Choosing a provider for Ozempic — clinical-oversight specifics
Because Ozempic is an FDA-approved diabetes medication, the prescribing bar is different from weight-loss-only programs. You want a provider who: (1) screens for diabetic retinopathy before starting; (2) adjusts sulfonylurea or insulin doses appropriately at initiation; (3) tracks HbA1c quarterly; (4) catches hypoglycemia early. Pure weight-loss telehealth programs are typically not the right fit for diabetes management — but a few of the providers we track do handle T2DM rigorously.
Among the 48 GLP-1 telehealth providers we track, Eden Health (8.9/10) is our highest-rated for medical oversight: board-certified obesity medicine physicians, quarterly blood panels included (covers HbA1c, kidney function, lipid panel), and a published protocol for dose-hold during intolerable side effects. For patients with T2DM specifically, an in-network endocrinologist or PCP is often the better long-term fit than telehealth alone — but Eden Health is a reasonable bridge if you need faster access.
See how all 48 providers score on clinical oversight in the full rankings, or take the 60-second match quiz to find providers that fit your support needs.
Related
- Wegovy side effects deep dive — semaglutide at the higher 2.4mg weight-loss dose
- Zepbound side effects deep dive — tirzepatide for weight loss
- Mounjaro side effects deep dive — Eli Lilly's diabetes equivalent (tirzepatide)
- Foundayo side effects deep dive — the new oral GLP-1
- Ozempic vs Wegovy: same molecule, different indications — when each is appropriate
- Cross-drug GLP-1 side effects comparison
- FDA warning letter tracker — 50+ enforcement actions against GLP-1 providers since 2025
- Provider safety checker — verify any GLP-1 telehealth program before enrolling
Sources
- Ozempic (semaglutide) FDA-approved prescribing information — DailyMed
- Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) — NEJM 2016
- FDA MedWatch — adverse event reporting
- 988 Suicide & Crisis Lifeline
This page is for informational purposes only and is not medical advice. Always discuss medication decisions with a licensed prescriber. Ozempic is FDA-approved for type 2 diabetes mellitus and cardiovascular risk reduction in adults with T2DM. Side-effect rates are population averages from clinical trials and may not reflect your individual experience. If you are experiencing a medical emergency, call 911.